Tanvex Biopharma, Inc.TWSE: 6541

Appointment of the Chief Executive Officer and Chief Financial Officer (CFO)/Accounting officer

· Issued by Tanvex BioPharma, Inc.
Close
Today's Information

Provided by: Tanvex BioPharma, Inc.
SEQ_NO 7 Date of announcement 2022/02/18 Time of announcement 21:54:45
Subject 
 Appointment of the Chief Executive Officer
and Chief Financial Officer (CFO)/Accounting officer
Date of events 2022/02/18 To which item it meets paragraph 8
Statement 
1.Type of personnel changed (please enter: spokesperson, acting
  spokesperson, important personnel (CEO, COO, CMO, CSO, etc.)
,financial officer, accounting officer, corporate governance officer,
research and development officer, chief internal auditor, or
designated and non-designated representatives):Chief Executive Officer
and Chief Financial Officer (CFO)/Accounting officer
2.Date of occurrence of the change:2022/02/18
3.Name, title, and resume of the previous position holder:N/A
4.Name, title, and resume of the new position holder:
Yun Yen/CEO
Peter K.H. Lin/CFO and Accounting officer
5.Type of the change (please enter: "resignation", "position
adjustment", "dismissal", "retirement", "death" or "new
replacement"):New Appointment
6.Reason for the change:New Appointment
7.Effective date:2022/02/18
8.Any other matters that need to be specified:None

Company analysis